Condition Directory

Ovarian Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Ovarian Cancer. Browse Ovarian Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 8, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

319

Shown on this page

Current sort

How Ovarian Cancer studies are organized in the registry

Ovarian cancer records are commonly registered as a group — “ovarian, fallopian tube, or primary peritoneal cancer” — so the broader phrasing is normal and not a labeling error. Platinum-sensitivity language (“platinum-resistant,” “platinum-sensitive”) and BRCA status frequently define the study population in titles.

Terms that often appear in related listings

platinum-resistant fallopian tube BRCA PARP

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 319 matching trials for Ovarian Cancer.

Live ClinicalTrials.gov results.

Active filters: "platinum-resistant" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Interventions: Atovaquone, Biopsy, Computed Tomography, Paracentesis; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more

Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Interventions: azenosertib; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions: ATX-295, ATX-295 and bevacizumab (or biosimilar); Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more

Conditions: Platinum-resistant Ovarian Cancer
Interventions: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 72
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more

Conditions: Ovarian Cancer
Interventions: Nivolumab, Etigilimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more

Conditions: Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
Interventions: TROP2-CAR-NK, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Interventions: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more

Conditions: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions: ONC-392, Pembrolizumab; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 21
States / cities: Goodyear, Arizona • Phoenix, Arizona • Danbury, Connecticut + 18 more

Conditions: Platinum Resistant Ovarian Cancer
Interventions: losartan, Paclitaxel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 69 more

About this Ovarian Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ovarian Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ovarian Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ovarian Cancer clinical trials

How Ovarian Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

About this Ovarian Cancer clinical trials directory page